Gene-Guided chemo aims to boost surgery success in stomach cancer

NCT ID NCT02366819

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot trial tests whether using a patient's genetic profile to determine the dose of irinotecan (a chemotherapy drug) can improve outcomes for people with advanced stomach or esophageal cancer. The study combines chemotherapy before and after surgery, with the goal of increasing the chance of a complete tumor removal. It involves 36 participants and is currently suspended.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Chemotherapy drugs (oxaliplatin, leucovorin calcium, irinotecan hydrochloride, fluorouracil) plus surgery
What this could lead to
If successful, this could show that tailoring chemo doses based on a patient's genes reduces side effects and improves the chance of successful surgery.
What could go wrong
This is a small pilot trial (36 people) that has been suspended, so results are uncertain. The approach may not work for all patients or may still cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Kellogg Cancer Center - Evanston Hospital

    Evanston, Illinois, 60201, United States

  • NorthShore University HealthSystem

    Evanston, Illinois, 60201, United States

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.